Are the Abbvie shares stuck in the mud until the street gets some visibility about the earnings impact of the Gilead price war on HCV drugs and the Humira copies hitting in 2017? Who knows? My opinion is that the shares will do the opposite of what the street thinks they will do.
The weekly chart of ABBV is still intact  even though its had decent distribution of late.
Some say buy and some say sell – That is what makes a market.
Time will tell as always.
SMZ
